AgingResearch.NewsJoin free

Ne:tub1

Ne:tub1 has been studied in 1 paper since 2025: none in people yet, 1 in cells. No study of it in people or animals has been published yet. The newest paper, Feb 3, 2025: “Development and Characterization of Magnetic Nanoemulsion-Based Senolytic Peptides for Osteoarthritis Treatment”.

Intervention

1 paper studies it1 findingUpdated

More peptides

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Axencia Galega de Innovación and 6 more
  • 1 of 1 finding with company ties
  • Cells1

What did studies of Ne:tub1 find?

1

Studies of Ne:tub1 measured 1 outcome; the most studied are Cellular retention (1 study).

Cellular retention

upin human cells1

1 study

  1. Ne:tub1 increases cellular retention in human cells.

    “Improved cellular retention and therapeutic effects of the associated TUB1 peptide, compared to its free form, have been demonstrated”

    Cellscompared to free TUB1

    Development and Characterization of Magnetic Nanoemulsion-Based Senolytic Peptides for Osteoarthritis Treatment

    International journal of molecular sciences

Latest

Related